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Abstract
Purpose: Bayesian hierarchical models (BHMs) have been used to identify adverse
drug reactions, allowing information sharing amongst adverse reactions and drugs
expected to have similar properties. This study evaluated the use of BHMs in the
routine signal detection analyses of potential first-trimester teratogens, where these
models have not previously been applied.
Methods: Data on 15 058 malformed foetuses exposed to first trimester medications
(1995-2011) from 13 European congenital anomaly (CA) registries were analysed.
The proportion of each CA in women taking a specific medication was compared with
the proportion of that CA in all other women in the dataset (55 CAs × 523 medica-
tions). BHMs were grouped by either medications or CAs or by both simultaneously,
and the results compared with analysing each medication-CA combination separately
and adjusting for multiplicity using a double false discovery rate (FDR) procedure.
The proportions of “high-risk” medications (medications which have been shown to
carry a moderate to high risk of foetal malformations) identified as potential signals
were compared, as well as the total number of potential signals requiring follow up
(the effective workload).
Results: BHMs identified more high-risk medications than the double FDR method,
but the effective workload was larger. A BHM grouping both medications and CAs,
for example, identified 23% of high-risk medications compared with 14% by the dou-
ble FDR; however, there was an increase from 16 to 71 potential signals requiring
follow up.
Conclusion: For comparable effective workloads, BHMs did not outperform the dou-
ble FDR, which is comparatively straightforward to implement and is therefore rec-
ommended for continued use in teratogenic signal detection analyses.
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1 | INTRODUCTION
Pregnant women are excluded from the majority of new medication
safety studies, so information about potential risks to a foetus is lacking.
Routine screening of congenital anomaly (CA) data for potentially terato-
genic medications taken during the first trimester of pregnancy is per-
formed by EUROmediCAT.1 EUROmediCAT compares the odds of
exposure to a specific medication for a specific CA with the odds of
exposure to the same medication for all other medication-exposed CAs2
using a double false discovery rate (FDR) procedure to incorporate group-
ings of similar medications when adjusting for multiple testing.3
In the field of pharmacovigilance, large spontaneous reporting data-
bases detect signals of adverse events (AEs) using disproportionality ana-
lyses to identify drug-AE combinations with more observed reports than
expected under the assumption of independence.4 Bayesian hierarchical
models (BHMs) have been applied to these spontaneous reporting
datasets,5 with the aim of improving estimated associations for any drug-
AE combination by incorporating information from other similar drugs
(or AEs) using specified groupings.6 BHMs can explicitly allow (without
imposing) for the possibility that different medications in the same group
might be related and that AE rates are more likely to be similar within
than across these groups. A BHM with information sharing in two
dimensions has also been proposed to incorporate groupings of both
medications and AEs simultaneously.7 Simulation studies and application
to a sample of the World Health Organisation pharmacovigilance data-
base have demonstrated that a two-dimensional model of information
sharing can produce a more powerful BHM to detect true adverse drug
reactions, compared with sharing information only in one dimension.7
We aimed to ascertain whether BHMs that share information between
medications and/or CAs using existing coding hierarchies have the
potential to improve the effectiveness of signal detection methods using
EUROmediCAT data.
2 | METHODS
2.1 | Study population
EUROCAT is a network of European population based CA registries
whose data is obtained through both active case finding and voluntary
reporting,8 with multiple sources of information used to ascertain CA
cases including live birth, foetal death, and termination of pregnancy
for foetal anomaly. Data quality indicators are used to assess consis-
tency of inclusion criteria, data collection, and recording across regis-
tries.9 The International Classification of Diseases coding version
10 with British Paediatric Association extension (IDC10-BPA) is used
to code CAs according to EUROCAT guidelines. EUROmediCAT com-
prises EUROCAT registries that collect information on first-trimester
(defined as the first day of a woman's last menstrual period up to her
12th gestational week) medication use. Maternal medication exposure
data is primarily obtained through prospectively recorded maternity
records, with additional sources including maternal interviews and
general practitioner records.10,11 Data on 31 197 malformed foetuses
with first-trimester medication exposures from 1995 to 2011 were
available for this study, covering a population of around 7 million
births across 13 registries in 11 countries. For some registries, there
was considerable data loss where it was not possible to verify the
timing of reported medication exposures, which has been discussed
previously (6). However, the distribution of types of CA were similar
for those pregnancies included and excluded due to unknown timing,
suggesting that cases remaining in the dataset for these registries
should not be prone to selection biases in this respect. Ethical and
data access approvals were obtained for each database from the rele-
vant governance infrastructures. This EUROmediCAT dataset was
used previously to compare different FDR methods for multiple test-
ing adjustment,3 and a large proportion of this data was also previ-
ously analysed for signal detection purposes.2
2.2 | Congenital anomalies and medication
exposures
Cases with chromosomal anomalies, skeletal dysplasia, genetic syn-
dromes, and microdeletions were excluded as they are unlikely to be
caused by teratogenic medications. The aetiology of congenital dislo-
cation of the hip is mechanical, so foetuses with this being their only
recorded major CA were also excluded (n = 905). EUROCAT's hierar-
chical coding system categorises the 54 nonchromosomal CA sub-
groups into 11 main organ system groups and five “other anomalies/
syndromes” subgroups https://eu-rd-platform.jrc.ec.europa.eu/sites/
default/files/Full_Guide_1_4_version_28_DEC2018.pdf.12 Five hun-
dred forty-two foetuses with a congenital heart defect (CHD) but no
information regarding the specific type of CHD were combined into
an additional subgroup (“unspecified CHD”; Table S1.
The Anatomical Therapeutic Chemical (ATC) system13 is used to
code unlimited exposures in EUROmediCAT data. The ATC coding
Key Points
• Bayesian hierarchical models have the potential to
improve teratogenic signal detection by incorporating
information sharing between similar medications and/or
congenital anomalies.
• In our analysis, Bayesian hierarchical models demon-
strated a potential to detect signals with fewer exposed
cases than the current frequentist signal detection
procedure.
• In our analysis of prospectively collected registry data on
congenital anomalies, Bayesian hierarchical models did
not outperform the currently used double false discovery
rate (FDR) method of adjusting for multiple testing in sig-
nal detection; continued use of double FDR methods are
therefore recommended for teratogenic signal detection.
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system has a hierarchical structure, grouping medications at five
levels; the highest (ATC1) groups medications into 14 main anatomical
groups, the next three (ATC2-4) use three to five digit codes, respec-
tively, to represent further therapeutic, pharmacological, and/or
chemical classifications, and the most detailed level (ATC5) uses seven
digits to identify the chemical substance. Older ATC codes subject to
alterations over time14 were updated to the newer codes. Foetuses
exposed only to vitamins, minerals, and/or folic acid were excluded.
Foetuses were excluded if exposed only to topical medications, codes
with less than five digits (detail below ATC4 level; n = 1219), second/
third trimester medications (n = 1490), or with unknown timing
(n = 12 073). Further description of these exclusions by registry have
been described in more detail in our previous study.3 After these
exclusions, a total of 15 058 malformed foetuses were included in the
analysis dataset. ATC5 codes were analysed, but where information
was only available to ATC4 level, this was also included. Five hundred
twenty-three medications with at least three exposed foetuses were
investigated. As in the previous EUROmediCAT analysis, foetuses
exposed only to medications with fewer than three exposures in total
were included in the dataset as controls (since medications with fewer
than three exposures are not analysed for signal detection).2,3
2.3 | Statistical analysis
Results from BHMs were directly compared with those obtained pre-
viously for the double FDR procedure on the same dataset.3 Briefly,
the double FDR comprises two steps15,16: first, a representative mini-
mum P value is calculated for each group and only those groups with
a representative P value below the specified FDR threshold are
included in the next step. In the second step, a Simes FDR procedure
is applied across all combinations belonging to those groups passing
the first step. All data management and calculations for Fisher's exact
test and the double FDR procedure were performed using Stata 12.17
For the BHMs, a Gamma Poisson Shrinker (GPS) and a BHM with
a Poisson distribution were combined to model the CA and medica-
tion counts.7 The expected count Eij for each observed count cij was
calculated using the marginal totals for medication i and CA j assuming
no association between i and j. The proportional reporting ratio
(PRR)18 for medication i and CA j was the ratio of the observed to
expected counts, PRRij =
cij
Eij
. The data structure for two-dimensional
information sharing by medications and CAs is displayed in Table 1.
Here, d represents ATC3 medication codes with D groups and i = 1, …,
nd medications within each group d and a denotes groupings of CAs
according to the EUROCAT organ system classes with A groups of
CAs and j = 1, …, na CAs within each group. The lighter grey shading in
Table 1 represents the set of the d = 2 group of medications crossed
with the a = 2 group of CAs, and the dark grey cell in Table 1 c2122
denotes the observed count for the combination of medication
i = 1 in the d = 2 medication group with CA j = 2 in the a = 2 CA group.
Each set in Table 1 has a group distribution, such that each medication-
CA combination within that two-way group shares a common prior dis-
tribution. There is also a prior distribution for the set of all top-level
sets, that is, an average across all CAs and/or medications.
Table S2 presents notation for the BHMs, for which a Poisson
distribution was used to model the observed counts cij for each com-
bination of a medication i and a CA j according to four models of
information sharing. Model 1 is a separate BHM for each medication-
CA combination, with no grouping of medications or CAs. Models
2 and 3 are one-dimensional models of information sharing, with
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grouping for medications only (using ATC3 codes, model 2) or CAs
only (using EUROCAT organ system classes, model 3). In model 2, the
effects for each group of medications are calculated separately for
each CA, allowing a different distribution for each CA. Conversely, a
different distribution is allowed for each medication when grouping
by CAs in model 3. As a sensitivity analysis, an alternative formulation
of model 2 was also considered where CAs were treated as coming
from one overall group, imposing a common distribution of effects
across the group of all CAs, separately for each group of ATC3 medi-
cations (and vice-versa for model 3). For model 2, this allowed a more
direct comparison with the double FDR method, which groups medi-
cations using ATC3 codes but adjusts for multiple testing across all
CAs. Model 4 is two-dimensional in that groupings of both medica-
tions and CAs are incorporated, as displayed in Table 1. The minimally
informative priors used throughout are described in Section S1;
normal distributions were used for estimation of means (eg, average
PRRs for each medication/CA or group of medications/CAs), and uni-
form distributions were used for variance parameters.19 Minimally
informative priors were used, as our main aim was to assess the effect
of the groupings themselves on the model results, with the main
source of “informative” prior information therefore coming from the
groupings that were used. Different choices of values for the parame-
ters of prior distributions were assessed for their effect on model fit
and results. BHMs were implemented using JAGS via R package
rjags.20,21 The code used to specify these models in JAGS is presented
in Table S2. The coda package22 in R was used to assess model con-
vergence and to summarise the posterior distribution for each param-
eter, including convergence statistics and visual inspection of trace,
density and auto-correlation plots for the parameters in each model.
These measures were also used to determine the required number of
total iterations and thinning.
Any medication-CA combination with a posterior 2.5th percentile
(ie, the lower limit of a one-sided 97.5% posterior confidence interval
[PCI]) greater than 1 for the PRR was considered a potential signal. As
this choice of threshold is somewhat arbitrary, the effect of choosing
a stricter 0.5th percentile as a cut-off was also assessed. As the pur-
pose of signal detection is to screen for potential teratogens, combi-
nations are only flagged as potential signals if they represent an
increased in reporting (ie, PRR > 1). The number of associations with a
PRR < 1 (medications relatively “less harmful” for a specific CA than
the average medication in the dataset) and corresponding 97.5th
(or 99.5th) percentile less than 1 were monitored to determine how
often these occurred.
2.4 | Evaluation and comparison of signal
detection methods
Although risk classification systems have been implemented and
used in a number of countries including Australia, the United
States, and Sweden,23-25 a key challenge in the assessment of
signal detection methods for CA data is that there is no “gold stan-
dard” for classifying risks according to specific CAs.26,27 The
Australian government Department of Health provides an online
database of recorded pregnancy related risks associated with
medicines,25 and this categorisation system was used to indepen-
dently identify medications for which there has been evidence of
high teratogenic risk. All medications are divided into five lettered
categories, with category A medications being considered safe for
use during pregnancy. Medications in category B are those which
have not shown evidence of harmful effects to human foetuses;
category C medications may carry harmful effects to human foe-
tuses, but with no evidence of causing CAs. Categories D and
X medications are believed to increase the frequency of human
foetal malformations, carrying a moderate to high-risk. The
Australian classification system does not distinguish risks for spe-
cific CAs. The total number of “high-risk” medications identified
by each model was compared, as well as the proportion of medica-
tions identified as potential signals out of the total number of
high-risk medications in the data. This is called the identification
rate, and is defined as follows:
Identification rate
=
Number of “high-risk“medications identified as potential signals
Total number of “high-risk”medications in the data
The proportion of category A medications being identified as
potential signals was also considered, as a measure of the likely num-
ber of “false positive” associations. The total number of unique medi-
cations in the set of potential signals identified by each method is
referred to as the “effective workload.” Note that we refer only to
potential signals as the aim of this study is to assess signal generation
methods for CA data, and we do not further evaluate the potential
signals here (since this has already been done for this dataset28).
3 | RESULTS
3.1 | Description of signal detection dataset
Data on 15 058 malformed foetuses were available for analysis with
55 CAs in 16 organ system groups (see Table S1): an average of 4.5
CAs per group. Half of the groups had only one CA, and the largest
group (congenital heart disease) included 17 CAs (specific heart anom-
alies). There were 1.6 recorded medication exposures per pregnancy
on average, ranging from one (in 65% of cases) up to 16 (in one
case). The number of ATC medications with at least three exposures
in the data was 523, of which 39 (7.5%) were coded only to ATC4.
The total number of recorded exposures to these medications was
22 624. There were 28 765 potential medication-CA combinations
(523 medications × 55 CAs) and 116 ATC3 groups, with an average
of nine (range 1-20) medications and 487 (range 53-1086)
medication-CA combinations per group.
Of the 523 medications in the signal detection analyses,
44 (8.4%) were high-risk, 297 (57%) were “low risk” (of which 77 were
category A medications), and the other 182 medications (35%) were
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not present in the Australian categorisation system database (coded
as “unclassified risk”). Three medications mapped to a code in both
the low-risk and high-risk group depending on their dosage; there is
no information on dosage in EUROmediCAT data, so these medica-
tions were assigned to the unclassified risk category. Of 116 ATC3
groups, 94 (81%) contained no high-risk medications, 13 (11%) con-
tained one high-risk medication, and nine (8%) groups contained at
least two high-risk medications.
3.2 | Signal detection analysis
Table 2 and Figure 1 present key results from the four BHMs and the
double FDR procedure, according to the two thresholds used to
define potential signals for BHMs (95% and 99% PCIs) and for FDR
cut-offs varying from 5% to 50%. A cut-off of 5% (FDR 5%), for exam-
ple, means that up to 5% of the potential signals in the double FDR
analysis might be expected to be false positive associations. The num-
ber of potential high-risk medication signals identified by each
method is displayed in Figure 1, which plots the identification rate
against the effective workload. Table 2 shows that the number of
ATC3 groups with at least one potential signal decreased as the
cut-off level for each method became stricter and fewer potential
signals were identified. The effective workload is also shown for
each method (in bold), including a breakdown by risk categories.
Table 2 and Figure 1 show that a one-dimensional BHM with
grouping by ATC3 and a 95% PCI cut-off resulted in the most
potential signals overall and identified the most high-risk DX medi-
cations as potential signals (identification rate = 48%). However,
this model also resulted in a very high effective workload (n = 160),
with 30% of all medications identified as potential signals and at
least one potential signal in over half the ATC3 groups. Individual
BHMs and those grouping only by CA gave similar results for a
95% PCI cut-off, though with fewer high-risk signals identified and
higher effective workloads. Using a stricter 99% PCI cut-off to
define potential signals always resulted in a lower identification
rate, but a higher proportion of the potential signals being for high-
risk medications. The proportion of category A medications identi-
fied as potential signals was lower than the high-risk proportion for
double FDR, but higher than the high-risk proportion for the major-
ity of BHMs. The “strictest” model was double FDR, especially at
lower thresholds, for example, double FDR 5% identified only three
potential signals (two high-risk). A BHM grouping both medications
and CAs with a 95% PCI threshold identified four more high-risk
medications (identification rate 23%) than double FDR 50% (identi-
fication rate 14%); however, this was at the expense of more than
a 4-fold increase in effective workload, from 16 medications to
71, for a gain in identification rate of only 9%. When using the 99%
PCI cut-off to define potential signals, the two-dimensional BHM
did not perform as well as the double FDR 50%.
Table S3 presents the overlap between the 16 potential medica-
tion signals from double FDR 50% and potential medication signals in
BHMs. BHMs with a 95% PCI and grouping by CAs or by both CAs
and ATC3 each did not include one of the double FDR medication sig-
nals, although the double FDR signal not present was for a different
medication in the two BHMs. The 99% PCI cut-off excluded more
double FDR signals, except for a BHM with no grouping and a 99%
PCI cut-off, which included all 16 potential signals from double FDR.
Results from the alternative one-dimensional models (averaging over
the ungrouped dimension) are presented in Table S4. These models
resulted in low effective workloads and identification rates, more
comparable with those using a double FDR. Double FDR 50% and its
“equivalent” one-dimensional BHM with grouping by ATC3 and aver-
aging over CAs resulted in 16 and 15 medications being identified as
potential signals, respectively (Table S4). However, two more high-risk
medications (six vs four) were identified by double FDR.
The number of “less harmful” associations according to each method
is presented in Table S5, along with the total number of combinations
identified as potential signals (as shown in Table 2) for comparison pur-
poses. Double FDR resulted in only three “less harmful” associations;
however, all of the BHMs resulted in a considerable number (up to 23 or
69 for models using a 99% or a 95% PCI threshold, respectively).
3.3 | Different potential signals according to
different methods: The effect of shrinkage in BHMs
As well as the overall number of potential signals, differences in which
medication-CA combinations were identified as potential signals in
the different methods were apparent. One situation where this
occurred was due to shrinkage to the null, where a potential signal
attenuates in some BHMs due to the influence of other combinations
in that group, as demonstrated in Figure S1. Shrinkage to the mean
can also occur if a strong association influences other combinations in
its group to create additional potential signals that are not present
without this shrinkage, for example, see Figure S2.
4 | DISCUSSION
Many BHMs considered in this study identified more of the high-
risk medications (higher identification rate) than the double FDR;
however, these improvements came at the expense of a substantial
increase in the effective workload, and therefore lower proportions
of the potential signals being for high-risk medications. Consider-
ing the simplicity of the double FDR method, we recommend that
the double FDR method continue to be used in practice for the
detection of potential signals of teratogenic medications using
EUROmediCAT data.
4.1 | Different potential signals according to FDR
and BHM approaches
BHMs incorporating information sharing could identify a greater num-
ber of potential high-risk medication signals than double FDR and
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strengthened the analysis of combinations with low cell counts by
using information in the surrounding cells, allowing them to be
included in the set of resulting potential signals (Table S5). In contrast,
the frequentist EUROmediCAT approach requires at least three expo-
sures to identify any association as a potential signal. This detection
of a potential medication signal for a newer drug with little data is one
of the potential advantages of BHMs in signal detection. Further
investigation is warranted to determine how likely it is that the addi-
tional potential signals detected by BHMs are true associations and
whether alternative model specifications could improve the power of
BHMs in this context. BHMs will be more powerful if similar drugs do
have similar teratogenic effects or if CAs in the same organ system
are affected by the same drugs.
4.2 | Evaluation and comparison of methods
The lack of existing knowledge regarding the teratogenic effect of
medications used during pregnancy makes it difficult to evaluate how
many teratogens are missed by each method and the possible reasons
for any lack of detection. A key limitation of using the Australian clas-
sification system is that high-risk medications are not identified in
association with a specific CA. In addition, categorisation of medica-
tions as B or C in the Australian database may indicate a lack of
evidence rather than meaning these medications are really low risk for
CAs. Furthermore, almost a third of the medications in the
EUROmediCAT data were not present in the Australian risk classifica-
tion database. In practice, teratogenic risk is nearly always specific to
certain CAs.29 This may have affected our “identification rate,” which
does not reflect the number of different CAs that a medication is
associated with. In this analysis, any associations arising due to con-
founding by indication cannot be identified. Our use of the risk
categorisation system here was not to judge the absolute strengths of
a signal detection procedure, but rather to directly compare methods
in terms of the volume of potential signals and assessment of resulting
workload for follow up of identified associations; the limitations iden-
tified above should therefore be present across all models considered.
4.3 | Methodological considerations
An important assumption of the Poisson distribution is that events in
the data occur independently. However, in EUROmediCAT, a mal-
formed foetus often has multiple CAs and/or medication exposures
and certain CAs may be more likely to co-occur within pregnancies.
Similarly, exposure to a specific medication may increase the likeli-
hood of exposure to another medication, for example, it is common to





























number of medication signals
Double FDR (5%, 10%, 20%, 30%, 50%) BHM, 95% PCI cut-off BHM, 99% PCI cut-off
F IGURE 1 Identification rate vs effective workload: comparing the use of the double FDR procedure with Poisson Bayesian hierarchical
models (BHMs) using a 95% PCI and a 99% PCI as a cut-offs for definition of signals, for four types of grouping by congenital anomaly (CA) and/
or ATC medications
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case that if one particular medication is taken, any other medications
in that group will not be taken. In addition, twins with the same anom-
alies will violate the independence assumption. Approximately 3% of
foetuses in EUROmediCAT data are twin births, 5% of whom have
the same anomalies.30 Therefore, the occurrence of twins will not be
a serious violation of the independence assumption here. The occur-
rence of twins is further considered when following up identified
associations in greater detail.
Another potential consideration for our two-dimensional BHMs is
the way in which information sharing is specified around the
medication-CA combination of interest. It may be argued that our
BHM allows the count for the medication-CA combination of interest
(ie, the dark grey cell in Table 1) to contribute the model twice: first,
to generate a hypothesis about the data via the prior distribution, and
second, to test it. One solution might be to consider a model where
the count for the combination of interest itself is removed from the
prior distribution for that combination. Table 1 presented our two-
dimensional model, where the prior for any combination includes
information from all mediations and CAs within that set; an alternative
formulation could be to include only those combinations with either
the medication or CA in common with the combination of interest.
These possibilities require further investigation.
In any signal detection analysis using disproportionality mea-
sures, reporting biases for a common medication may lead to infla-
tion in the overall rates for that medication, meaning that other
associations in the database are masked.27,31,32 This is not thought
likely to occur in the EUROmediCAT as medication exposure is
generally collected before the CA diagnosis. Masking may also be
an issue in EUROmediCAT data through the use of malformed con-
trols if a proportion of the control group is related to the medica-
tion of interest. Studies have demonstrated that the removal of a
masking effect may help lead to new signals of public health rele-
vance being discovered.31,33 It is also thought, however, that sig-
nificant masking is not common in large spontaneous reporting
databases, and where present it mostly affects rarely reported
AEs.34-36 Confounding by co-reported medications can also occur
if two medications are frequently prescribed together but only one
causes the CA of interest.32 We may expect a teratogen to act in a
similar way regardless of where it is taken; however, certain medi-
cations may have varying usages and/or availability in different
EUROmediCAT registries and countries. As many medication-CA
combinations have very small numbers, the best approach to an
ongoing signal detection process is considered to be investigation
of any potential registry effects at a later stage in the analysis; as
such, after potential signals are generated, the next step of the
EUROmediCAT signal detection process includes the adjustment
of estimates for confounding by registry.28
This analysis excludes all chromosomal anomalies; these anoma-
lies could theoretically be analysed as a negative control outcome as
no medications are expected to be associated with any chromosomal
anomalies. However, the risk of a chromosomal anomaly is strongly
associated with maternal age, and methods to adjust for this con-
founder in signal detection analyses would need to be developed.
4.4 | Strengths and limitations of
EUROmediCAT data
The existing EUROCAT network, upon which EUROmediCAT is
based11, ensures that CAs are coded in a detailed and standardised
manner across all registries. Good agreement between medication
exposures recorded in the EUROmediCAT database and those
actually used has also been demonstrated.37 As maternal medica-
tion exposure data in EUROmediCAT registries is primarily
obtained through prospectively recorded maternity records, con-
founding by the time of pregnancy registration of adverse out-
comes is unlikely to have occurred. On the other hand, there is
known under ascertainment for certain medication exposures in
EUROmediCAT data, which may reduce the sensitivity of any signal
detection analysis.10,38 There is also a lack of information regarding
the dosage and precise timing of medication exposures. Although
the critical period of development for most major CAs occurs dur-
ing the second and third gestational months, the exact timing can
differ according to the type of CA and some CAs may also develop
after the first trimester of pregnancy.39-41 In this study, we cannot
determine whether medications were taken during the particular
critical period for development of each specific CA. As only mal-
formed foetuses exposed to at least one medication are included, it
is not possible to estimate the relative risk of a CA for medication
exposures compared with a healthy (ie, non-exposed and non-mal-
formed) control population.42
5 | SUMMARY AND CONCLUSIONS
Despite the difficulties in assessing the performance of the signal
detection methods, we recommend the double FDR method for con-
tinued use in signal detection analyses of EUROmediCAT data.
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